Management of familial cancer: Sequencing, surveillance and society

Nature Reviews Clinical Oncology

Volumn 11, Issue 12, 2014, Pages 723-731

  Samuel, Nardin ^a   Villani, Anita ^b   Fernandez, Conrad V ^c   Malkin, David ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c IWK HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG;

CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER PROGNOSIS; DNA SEQUENCE; FAMILIAL CANCER; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEALTH CARE POLICY; HUMAN; MEDICAL ETHICS; NEXT GENERATION SEQUENCING; ONCOGENE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; DISEASE MANAGEMENT; GENETICS; NEOPLASM; PROCEDURES; RISK ASSESSMENT;

DISEASE MANAGEMENT; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; NEOPLASMS; RISK ASSESSMENT;

EID: 84927176200     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.169     Document Type: Review

References (70)

1. Meyerson, M., Gabriel, S. & Getz, G. Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11, 685-696 (2010).
2. Schiffman, J. D. et al. Update on pediatric cancer predisposition syndromes. Pediatr. Blood Cancer 60, 1247-1252 (2013).
3. Bakry, D. et al. Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium. Eur. J. Cancer 50, 987-996 (2014).
4. Vasen, H. F. et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium "Care for CMMR-D" (C4CMMR-D). J. Med. Genet. 51, 283-293 (2014).
5. Hill, D. A. et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 325, 965 (2009).
6. Choong, C. S., Priest, J. R. & Foulkes, W. D. Exploring the endocrine manifestations of DICER1 mutations. Trends Mol. Med. 18, 503-505 (2012).
7. de Kock, L. et al. Germ-line and somatic DICER1 mutations in pineoblastoma. Acta Neuropathol. 128, 583-595 (2014).
8. Rothenberg, S. M. & Settleman, J. Discovering tumor suppressor genes through genome wide copy number analysis. Curr. Genomics 5, 297-310 (2010).
9. Costa, J. L., Meijer, G., Ylstra, B. & Caldas, C. Array comparative genomic hybridization copy number profiling: a new tool for translational research in solid malignancies. Semin. Radiat. Oncol. 18, 98-104 (2008).
10. Comino-Mendez, I. et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat. Genet. 43, 663-667 (2011).
11. Smith, M. J. et al. Loss of function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat. Genet. 45, 295-298 (2013).
12. Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat. Genet. 45, 1226-1231 (2013).
13. Stadler, Z. K., Schrader, K. A., Vijai, J., Robson, M. E. & Offit, K. Cancer genomics and inherited risk. J. Clin. Oncol. 32, 687-698 (2014).
14. Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 11, 726-734 (2011).
15. Lawlor, E. R. & Theiele, C. J. Epigenetic changes in pediatric solid tumors: promising new targets. Clin. Cancer Res. 18, 2768-2779 (2012).
16. Killian, J. K. et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 3, 648-657 (2013).
17. Choufani, S., Shuman, C. & Weksberg, R. Molecular findings in Beckwith-Wiedemann syndrome. Am. J. Med. Genet. C. Sem. Med. Genet. 163C, 131-140 (2013).
18. Mardis, E. R. Next-generation sequencing platforms. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 6, 287-303 (2013).
19. Idris, S. F., Ahmad, S. S., Scott, M. A., Vassiliou, G. S. & Hadfield, J. The role of high-throughput technologies in clinical cancer genomics. Expert Rev. Mol. Diagn. 13, 167-181 (2013).
20. Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302-308 (2014).
21. Meijers-Heijboer, H. et al. Low-penetrance susceptibility to breast cancer due to CHEK2∗1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31, 55-59 (2002).
22. Hu, H. et al. A unified test of linkage analysis and rare variant association for analysis of pedigree sequence data. Nat. Biotechnol. 32, 663-669 (2014).
23. Gartner, J. J. et al. Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc. Natl Acad. Sci. USA 110, 13481-13486 (2013).
24. Ward, L. D. & Kellis, M. Interpreting noncoding genetic variation in complex human traits and human disease. Nat. Biotechnol. 30, 1095-1106 (2012).
25. Turnbull, C. et al. Gene-gene interactions in breast cancer susceptibility. Hum. Mol. Genet. 21, 958-962 (2012).
26. Moorman, P. G. et al. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. Breast Cancer Res. Treat. 124, 441-451 (2010).
27. Samuel, N. & Hudson, T. J. Translating genomics to the clinic: implications of cancer heterogeneity. Clin. Chem. 59, 127-137 (2013).
28. Zhuang, Z. et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N. Engl. J. Med. 367, 922-930 (2012).
29. Scott, R. H. et al. Stratification of Wilms tumor by genetic and epigenetic analysis. Oncotarget 3, 327-335 (2012).
30. Behjati, S. et al. A pathogenic mosaic TP53 mutation in two germ layers detected by next generation sequencing. PLoS ONE 9, e96531 (2014).
31. Stein, L. D. An introduction to the informatics of "next-generation" sequencing. Curr. Protoc. Bioinformatics 11, 11.1 (2011).
32. Biesecker, L. G., Burke, W., Kohane, I., Plon, S. E. & Zimmern, R. Next-generation sequencing in the clinic: are we ready? Nat. Rev. Genet. 13, 818-824 (2012).
33. Knapke, S., Nagarajan, R., Correll, J., Kent, D. & Burns, K. Hereditary cancer risk assessment in a pediatric oncology follow-up clinic. Pediatr. Blood Cancer 58, 85-89 (2012).
34. Fernandez, C. V. et al. Attitudes of parents to the return of targeted and incidental genomic research findings in children. Genet. Med. 16, 633-640 (2014).
35. Ross, L. F., Saal, H. M., David, K. L., Anderson, R. R. & American Academy of Pediatrics; American College of Medical Genetics and Genomics. Technical report: ethical and policy issues in genetic testing and screening of children. Genet. Med. 15, 234-245 (2013).
36. Fabsitz, R. B. et al. Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ. Cardiovasc. Genet. 3, 574-580 (2010).
37. Wolf, S. M. Return of individual research results and incidental findings: facing the challenges of translational science. Annu. Rev. Genomics Hum. Genet. 14, 557-577 (2013).
38. Green, R. C. et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 15, 565-574 (2013).
39. American College of Medical Genetics and Genomics. ACMG Updates Recommendation on "Opt Out" for Genome Sequencing Return of Results [online], https://www.acmg.net/docs/Release-ACMGUpdatesRecommendations-final.pdf (2014).
40. McGuire, A. L. et al. Point-counterpoint. Ethics and genomic incidental findings. Science 340, 1047-1048 (2013).
41. Holm, I. A. et al. Guidelines for return of research results from pediatric genomic studies: deliberations of the Boston Children's Hospital Gene Partnership Informed Cohort Oversight Board. Genet. Med. 16, 547-552 (2014).
42. Clayton, E. W. et al. Addressing the ethical challenges in genetic testing and sequencing of children. Am. J. Bioeth. 14, 3-9 (2014).
43. Eckstein, L., Garrett, J. R. & Berkman, B. E. A framework for analyzing the ethics of disclosing genetic research findings. J. Law Med. Ethics 42, 190-207 (2014).
44. Fernandez, C. V. et al. Attitudes of Canadian researchers toward the return to participants of incidental and targeted genomic findings obtained in a pediatric research setting. Genet. Med. 15, 2558-2564 (2013).
45. Rasmussen, A. et al. Uptake of genetic testing and long-term surveillance in von Hippel-Lindau disease. BMC Med. Genet. 11, 4 (2010).
46. Barrow, P., Khan, M., Lalloo, F., Evans, D. G. & Hill, J. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br. J. Surg. 100, 1719-1731 (2013).
47. Brandi, M. L. et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86, 5658-5671 (2001).
48. Ramirez-Ortiz, M. A. et al. Diagnostic delay and sociodemographic predictors of stage at diagnosis and mortality in unilateral and bilateral retinoblastoma. Cancer Epidemiol. Biomarkers Prev. 23, 784-792 (2014).
49. Green, D. The evolution of treatment of Wilms tumor. J. Pediatr. Surg. 48, 14-19 (2013).
50. Ward, E., DeSantis, C., Robbins, A., Kohler, B. & Jemal, A. Childhood and adolescent cancer statistics, 2014. CA Cancer J. Clin. 64, 83-103 (2014).
51. Villani, A. et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 12, 559-567 (2011).
52. Broniscer, A. et al. Clinial and molecular characteristics of malignant transformation of low-grade glioma in children. J. Clin. Oncol. 25, 682-689 (2007).
53. Jasperson, K. W. et al. Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families. Fam. Cancer 13, 257-265 (2014).
54. Choyke, P. L., Siegel, M. J., Craft, A. W., Green, D. M. & DeBaun, M. R. Screening for Wilms tumor in children with Beckwith-Wiedemann syndrome or idiopathic hemihypertrophy. Med. Pediatr. Oncol. 32, 196-200 (1999).
55. Lammens, C. R. et al. Regular surveillance for Li-Fraumeni syndrome: advice, adherence and perceived benefits. Fam. Cancer 9, 647-654 (2010).
56. Rothschild, P. R. et al. Familial retinoblastoma: fundus screening schedule impact and guideline proposal. A retrospective study. Eye (Lond.) 25, 1555-1561 (2011).
57. Canadian Retinoblastoma Society. National Retinoblastoma Strategy Canadian Guidelines for Care: stratégie thérapeutique du rétinoblastome guide clinique canadien. Can. J. Ophthalmol. 44 (Suppl. 2), S1-S88 (2009).
58. Imhof, S. M., Moll, A. C., Schouten-van Meeteren, A. Y. Stage of presentation and visual outcome of patients screened for familial retinoblastoma: nationwide registration in the Netherlands. Br. J. Ophthalmol. 90, 875-878 (2006).
59. Cairns, S. R. et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59, 666-689 (2010).
60. Tan, T. Y. & Amor, D. J. Tumour surveillance in Beckwith-Wiedemann syndrome and hemihyperplasia: a critical review of the evidence and suggested guidelines for local practice. J. Paediatr. Child Health 42, 486-490 (2006).
61. McNeil, D. E., Brown, M., Ching, A. & DeBaun, M. R. Screening for Wilms tumor and hepatoblastoma in children with Beckwith-Wiedemann syndromes: a cost-effective model. Med. Pediatr. Oncol. 37, 349-356 (2001).
62. Clericuzio, C. L. et al. Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith-Wiedemann syndrome or isolated hemihyperplasia. J. Pediatr. 143, 270-272 (2003).
63. Poulsen, M. L., Budtz-Jørgensen, E. & Bisgaard, M. L. Surveillance in von Hippel-Lindau disease (vHL). Clin. Genet. 77, 49-59 (2010).
64. Listernick, R., Ferner, R. E., Liu, G. T. & Gutmann, D. H. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann. Neurol. 61, 189-198 (2007).
65. Bree, A. F., Shah, M. R. & BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am. J. Med. Genet. A 155A, 2091-2097 (2011).
66. Evans, D. G. et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br. J. Neurosurg. 19, 5-12 (2005).
67. Krueger, D. A., Northrup, H. & International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr. Neurol. 49, 255-265 (2013).
68. Geller, J. I., Leslie, N. D. & Yin, H. Malignant Rhabdoid Tumor Follow-up [online], http://emedicine.medscape.com/article/993084-followup#a2648 (2012).
69. Schultz, K. A. et al. Judicious DICER1 testing and surveillance imaging facilitates early diagnosis and cure of pleuropulmonary blastoma. Pediatr. Blood Cancer 61, 1695-1697 (2014).
70. Doros, L. et al. DICER1-realted disorders (eds Pagon, R. A. et al.) in GeneReviews® [internet] (University of Washington; 2014).